Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Search
Streetvet: Free veterinary care
Learn more about StreetVet free veterinarian care for companion animals of the homeless
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
NexGard
Delivered in a highly palatable beef-flavoured chew that kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations in dogs and puppies.
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
PUREVAX®
PUREVAX® is the only fully adjuvant-free feline vaccine range.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
A beginner’s guide to fighting off cat parasites
Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics